Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease

Journal of Physiology

Volumn 575, Issue 2, 2006, Pages 411-416

  Greene, James G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE; PHOSPHATE; DOPAMINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MARCKS PROTEIN;

ADDICTION; BIPOLAR DISORDER; CELL SUBPOPULATION; CENTRAL NERVOUS SYSTEM; DEPRESSION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG TARGETING; ENERGY METABOLISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; MENTAL DISEASE; MITOCHONDRION; MOOD DISORDER; NERVE CELL PLASTICITY; NERVE FUNCTION; NEUROANATOMY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ARTICLE; BRAIN; LEWY BODY; NEUROTRANSMISSION; NONHUMAN;

ANIMALS; BRAIN; DOPAMINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MENTAL DISORDERS; NEURONS; PARKINSON DISEASE;

EID: 33747742435     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.112599     Document Type: Review

References (34)

1. Alfahel-Kakunda A & Silverman WF (1997). Calcium-binding proteins in the substantia nigra and ventral tegmental area during development: correlation with dopaminergic compartmentalization. Brain Res Dev Brain Res 103, 9-20.
2. Andersson JL, Marcus M, Nomikos GG & Svensson TH (1994). Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol 349, 236-243.
3. Bonci A, Bernardi G, Grillner P & Mercuri NB (2003). The dopamine-containing neuron: Maestro or simple musician in the orchestra of addiction?Trends Pharmacol Sci 24, 172-177.
4. Calabrese B & Halpain S (2005). Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 48, 77-90.
5. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L & Isacson O (2005). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14, 1709-1725.
6. Dassesse D, Hemmens B, Cuvelier L & Resibois A (1997). GTP-cyclohydrolase-I like immunoreactivity in rat brain. Brain Res 777, 187-201.
7. Dawson T, Mandir A & Lee M (2002). Animal models of PD: Pieces of the same puzzle?Neuron 35, 219-222.
8. Fasulo WH & Hemby SE (2003). Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. J Neurochem 87, 205-219.
9. Garcia-Segura LM, Perez J, Pons S, Rejas MT & Torres-Aleman I (1991). Localization of insulin-like growth factor I (IGF-I) -like immunoreactivity in the developing and adult rat brain. Brain Res 560, 167-174.
10. Greene JG, Dingledine R & Greenamyre JT (2005). Gene expression profiling of rat midbrain dopamine neurons: Implications for selective vulnerability in parkinsonism. Neurobiol Dis 18, 19-31.
11. Grimm J, Mueller A, Hefti F & Rosenthal A (2004). Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci U S A 101, 13891-13896.
12. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR et al. (2005). Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 62, 917-921.
13. Hedou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Artault JC et al. (2000). Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol 426, 549-560.
14. Hirsch E, Graybiel AM & Agid YA (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
15. Hurd YL, Pristupa ZB, Herman MM, Niznik HB & Kleinman JE (1994). The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience 63, 357-362.
16. Inaba S, Li C, Shi YE, Song DQ, Jiang JD & Liu J (2005). Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat 94, 25-35.
17. Kress GJ & Reynolds IJ (2005). Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol Dis 20, 639-645.
18. Liang CL, Sinton CM, Sonsalla PK & German DC (1996). Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5, 313-318.
19. Lu L, Neff F, Alvarez-Fischer D, Henze C, Xie Y, Oertel WH, Schlegel J & Hartmann A (2005). Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol 195, 27-39.
20. McCaffery P & Drager UC (1994). High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci U S A 91, 7772-7776.
21. McNamara RK, Hyde TM, Kleinman JE & Lenox RH (1999). Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. J Clin Psychiatry 60 (Suppl. 2), 21-26; Discussion 40-1, 113-116.
22. Massi M, Panocka I & de Caro G (2000). The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides 21, 1597-1609.
23. Matus A (2005). MARCKS for maintenance in dendritic spines. Neuron 48, 4-5.
24. Nestler EJ & Carlezon WA Jr (2006). The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 12, 1151-1159.
25. Paradis E, Clement S, Julien P & Ven Murthy MR (2003). Lipoprotein lipase affects the survival and differentiation of neural cells exposed to very low density lipoprotein. J Biol Chem 278, 9698-9705.
26. Prakash N & Wurst W (2006). Development of dopaminergic neurons in the mammalian brain. Cell Mol Life Sci 63, 187-206.
27. Reglodi D, Lubics A, Tamas A, Szalontay L & Lengvari I (2004). Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav Brain Res 151, 303-312.
28. Schein JC, Hunter DD & Roffler-Tarlov S (1998). Girk2 expression in the ventral midbrain, cerebellum, and olfactory bulb and its relationship to the murine mutation weaver. Dev Biol 204, 432-450.
29. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ & Gall CM (1994). Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342, 321-334.
30. Seroogy K, Schalling M, Brene S, Dagerlind A, Chai SY, Hokfelt T et al. (1989). Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: Peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry. Exp Brain Res 74, 149-162.
31. Shigemoto R, Nakanishi S & Mizuno N (1992). Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: An in situ hybridization study in adult and developing rat. J Comp Neurol 322, 121-135.
32. Takei N, Skoglosa Y & Lindholm D (1998). Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons. J Neurosci Res 54, 698-706.
33. Tang WX, Fasulo WH, Mash DC & Hemby SE (2003). Molecular profiling of midbrain dopamine regions in cocaine overdose victims. J Neurochem 85, 911-924.
34. Wang L, Liu X & Lenox RH (2001). Transcriptional down-regulation of MARCKS gene expression in immortalized hippocampal cells by lithium. J Neurochem 79, 816-825.